NCT01092104已完成1 期
A Proof of Concept, Multiple Dose-Escalating Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 52
- 主要终点
- HIV-1 RNA Change from Baseline
研究概览
简要总结
A double-blind, randomized, placebo-controlled, dose-escalating study to assess the antiviral activity, safety, tolerability, and pharmacokinetics (PK) of the CCR5 antagonist TBR 652 monotherapy dosed orally once daily (QD) for 10 days in HIV 1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naïve patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •No clinically significant findings on Screening evaluations (clinical, laboratory, and ECG), which in the opinion of the Investigator would interfere with the subject's ability to comply with the protocol.
- •Antiretroviral treatment-experienced; no antiretroviral therapy for at least 6 weeks prior to study entry.
- •CCR5 antagonist therapy naive.
- •CD4 cell count >/= 250 cells/mm3 during Screening (within 30 days prior to first dose).
- •Two separate qualifying plasma HIV 1 RNA levels >/= 5,000 copies/mL within 45 days prior to first dose.
- •Females who are not of reproductive potential (documented to be surgically sterile or postmenopausal [defined as amenorrhea ≥ 1 year and follicle stimulating hormone {FSH} ≥ 30 mU/mL]).
- •Females of child-bearing potential may be enrolled following a negative serum pregnancy test. If participating in activity that could lead to pregnancy, males and females shall agree to use two forms of barrier method contraception during the trial and for 2 months after stopping the medication.
排除标准
- •Presence of CXCR4- or dual/mixed-tropic HIV 1 virus.
- •Active CDC category C disease (except cutaneous Kaposi's sarcoma not requiring systemic therapy during the trial).
- •History of infection with hepatitis B or hepatitis C virus, history of cirrhosis, or any known active or chronic liver disease. NOTE: Hepatitis B vaccinated patients are eligible.
- •Serum ALT or AST values greater than Grade 1 or bilirubin values greater than the upper limit of normal (ULN) at Screening.
- •History of HIV-
- •Recent history (< 30 days prior to study drug administration) of clinically significant infection.
- •Pregnant females or females who are breastfeeding.
- •Treatment with immunomodulating agents (such as systemic corticosteroids, interleukins, interferons) or any agent with known anti-HIV activity within 30 days prior to study drug administration.
- •Treatment with any vaccine within 30 days of study drug administration.
- •A positive pre-study drug screen, including amphetamines, barbiturates, cocaine, or PCP.
- •Anticipated use of antacids during the trial and/or within 7 days prior to first dose of study drug.
- •Current alcohol or drug use, which in the expert judgment of the investigator, will interfere with the patient's ability to comply with the protocol requirements.
- •Inability, in the opinion of the investigator, to comply with the dosing schedule and protocol evaluations.
- •Use of any experimental medications within 4 weeks prior to Screening.
- •Current (within 30 days prior to the first dose of study drug) or anticipated use of antimetabolites; alkylating agents; or drugs, herbal preparations, and foods (including grapefruit) known to affect the CYP 3A4 or CYP 2C8 enzymes or P-glycoprotein transporters.
- •History of clinically significant hepatic, metabolic, endocrine, renal, hematologic, pulmonary, gastrointestinal, or cardiovascular disorders (including ECG abnormalities).
- •Uncontrolled hypertension.
- •Presence of a malabsorption syndrome affecting drug absorption (e.g., Crohn's disease, chronic pancreatitis).
- •History of malignancy with exception of cured basal or squamous cell carcinoma of the skin.
- •Receipt of radiation or cytotoxic chemotherapeutic agents and not recovered from side effects prior to the first dose of study medication.
- •Subjects who have used any over-the-counter medications (including phytotherapeutic, herbal, or plant-derived preparations) within 14 days prior to the first dose of study medication, unless approved by the Investigator, or who have used St. John's wort within 21 days prior to the first dose of study drug. (St. John's wort is prohibited during the study.)
- •History or presence of an abnormal ECG.
研究组 & 干预措施
TBR-652 75 mg QD
Experimental
TBR-652 75 mg QD for 10 days
干预措施: TBR-652 75 mg (Drug)
TBR-652 25 mg QD
Experimental
TBR 25 mg QD for 10 days
干预措施: TBR-652 (Drug)
Placebo
Placebo Comparator
Matching Placebo QD for 10 days
干预措施: TBR-652 Matching Placebo (Drug)
TBR-652 50 mg QD
Experimental
TBR-652 50 mg QD for 10 days
干预措施: TBR-652 50 mg (Drug)
TBR-652 100 mg QD
Experimental
TBR-652 100 mg QD for 10 days
干预措施: TBR-652 100 mg (Drug)
TBR-652 150 mg
Experimental
TBR-652 150 mg QD for 10 days
干预措施: TBR-652 150 mg (Drug)
结局指标
主要结局
HIV-1 RNA Change from Baseline
时间窗: 10 days
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve SubjectsChronic Hepatitis C (HCV)NCT00807001Merck Sharp & Dohme LLC41
已完成
1 期
Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis CChronic Hepatitis CNCT00227435Merck Sharp & Dohme LLC
已完成
1 期
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult ParticipantsHIV InfectionsNCT04212091National Institute of Allergy and Infectious Diseases (NIAID)33
终止
2 期
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated PatientsHIV InfectionsNCT00294372Boehringer Ingelheim36
已完成
1 期
A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild DyslipidemiaMild DyslipidemiaNCT01105598Esperion Therapeutics, Inc.53